Skip to main content
Premium Trial:

Request an Annual Quote

Barley Genome to be Sequenced in Around Four Years

NEW YORK (GenomeWeb News) – An international group of scientists expects that by 2012 it will complete the sequencing of the barley genome, a program that could potentially increase survival and yield of the crop.
The effort to sequence the barley genome includes eight institutions in the US, Australia, Japan, Finland, Germany, and the UK, which together make up the International Barley Sequencing Consortium.
Andreas Graner, of the Leibniz Institute of Plant Genetics and Crop Plant Research, said in a statement that the partners “are providing active contribution toward sequencing the barley genome, which is aimed to be completed by 2012.’’
The plan was announced at the 10th International Barley Genetics Symposium, which is currently being held in Alexandria, Egypt, by the International Center for Agricultural Research in the Dry Areas and Bibliotheca Alexandrina.
“The better we have deciphered the genome of the plant, the better will be our understanding of its ability to produce more and its resistance to biotic and abiotic stresses,” Graner said in a statement.
Comprised of around 5.3 billion base pairs, the barley genome is almost twice as large as the human genome. 
’’Farmers will benefit by having improved varieties that can produce more yield. It would also help reduce input of fertilizers and chemical plant protection to facilitate more sustainable agriculture,’’ Graner continued.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.